• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cereno Scientific

5.40 SEK

+2.08 %

Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+2.08 %
+1.03 %
-13.46 %
-22.75 %
-22.75 %
-46.80 %
+673.64 %
+61.68 %
-10.17 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Read more
Market cap
1.75B SEK
Turnover
407.44K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.8
2026

Interim report Q2'26

4.11
2026

Interim report Q3'26

3.2
2027

Annual report '26

Regulatory press release30.06.2026, 07.27

Cereno Scientific Carries Out Directed Share Issue of SEK 60 Million at a Premium to the Latest Closing Price – Strengthens Position Ahead of Upcoming Value-Creating Phase

Cereno Scientific
Press release26.06.2026, 07.45

Cereno Scientific Reports EAP Analyses with CS1 in PAH: Majority of Completing Patients Achieved Stable or Improved Clinical Status over 12 Months

Cereno Scientific
Regulatory press release17.06.2026, 14.30

Cereno Scientific AB (publ) publishes report from the Annual General Meeting 2026

Cereno Scientific

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research17.06.2026, 10.56

Cereno Scientific expands CS1 patent coverage - Edison

Cereno Scientific has strengthened CS1’s commercial positioning with a third Canadian patent, extending protection in a strategically important pharmaceutical market. The patent, granted within CS1’s third patent family, covers delayed-release formulations...

Cereno Scientific
Press release12.06.2026, 09.20

Cereno Scientific Cereno Scientific Strengthens Patent Protection for CS1 in Key Market Canada

Cereno Scientific
Press release03.06.2026, 07.45

Cereno Scientific to present at BIO International Convention 2026 and advance global partnering discussions

Cereno Scientific
Third party research27.05.2026, 08.49

Cereno Scientific: Preclinical development for CS585 - Edison

Cereno Scientific has announced that its third asset, CS585 (a potent and selective agonist of the prostacyclin receptor), will be tested in preclinical disease model studies relating to antiphospholipid syndrome (APS), a rare autoimmune disease associated...

Cereno Scientific
Regulatory press release27.05.2026, 08.00

Cereno Scientific Publishes Interim Report for Q1 2026

Cereno Scientific
Press release26.05.2026, 07.45

Cereno Scientific Confirms First Volunteer Dosed in CS014 PK-bridging Study Supporting Phase II Development in PH-ILD

Cereno Scientific
Regulatory press release22.05.2026, 19.24

Cereno Scientific publishes Annual Report for 2025

Cereno Scientific
Press release21.05.2026, 07.45

Cereno Scientific to Initiate Preclinical Evaluation of CS585 in Rare Disease Antiphospholipid Syndrome (APS) Progressing toward Clinical Phase

Cereno Scientific
Regulatory press release15.05.2026, 14.30

Cereno Scientific give notice to attend the Annual General Meeting 2026

Cereno Scientific
Press release11.05.2026, 07.30

Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension

Cereno Scientific
Press release10.04.2026, 08.45

Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026

Cereno Scientific
Press release04.04.2026, 08.00

Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH

Cereno Scientific
Regulatory press release31.03.2026, 07.30

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program

Cereno Scientific
Press release27.03.2026, 11.09

Cereno Scientific: Stifel Initiates Coverage with Buy Rating and Price Target of SEK 20

Cereno Scientific
Third party research24.03.2026, 13.28

Cereno Scientific: Inflection points coming into view - Edison

Cereno Scientific’s FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226, we anticipate a step-up in clinical activity and partnering...

Cereno Scientific
Press release17.03.2026, 12.20

Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD

Cereno Scientific
Press release12.03.2026, 07.45

Cereno Scientific to Participate at BIO-Europe Spring and LSX World Congress Europe 2026 on March 23-26 in Lisbon

Cereno Scientific